Travere Therapeutics (TVTX) Jefferies Global Healthcare Conference summary

Company overview and pipeline

• Focused on rare kidney and metabolic diseases, with commercial and late-stage development programs.

• Filspari (sparsentan) received accelerated approval for IgA nephropathy and completed a landmark phase III trial in FSGS.

• Pegtibatinase, a phase III enzyme replacement therapy for HCU, targets a severe genetic disorder with significant unmet need.

• Plans to bring pegtibatinase through clinical development in the next few years.

Filspari commercial launch and performance

• Over 2,000 patient start forms received since launch, with strong quarter-over-quarter growth in demand and revenue.

• High payer coverage (95%+) and strong claims approval rates; most patients already on standard of care before Filspari.

• High compliance rates and positive patient feedback, with many reporting significant improvements.

• REMS process streamlined for physicians and patients, with improved education leading to increased uptake.

Market dynamics and competitive landscape

• Filspari positioned as foundational therapy for IgA nephropathy, with evidence from head-to-head trials against active comparators.

• SGLT2 inhibitors and Tarpeyo seen as complementary rather than competitive; Filspari offers greater proteinuria reduction.

• Uptake strong in both community and academic settings, with key opinion leaders prescribing post-data disclosure.

• Novartis' atrisentan data seen as supportive of the class, but Filspari offers higher efficacy and simpler dosing.